|
|
 |
|
Viewing report
|
|
|
|
Cancer Biomarkers: Enhancing Diagnostic, Therapeutic and Developmental Strategies
Datamonitor, May 2006, Pages: 73
The current focus on biomarker discovery is a result of an improved understanding of the biologic basis for carcinogenesis. The increasing number of potential drug targets and a plethora of diverse, new developmental agents have stimulated the search for biomarkers that can reduce the time, cost and attrition rates prevalent in oncology drug development.
Scope of this title:
- The role of biomarkers in optimizing patient selection and treatment outcomes and in expediting oncology drug development.
- Biomarker classification in oncology.
- Regulator opinion on the integration of novel, valid and relevant biomarker endpoints into the design of oncology clinical trials.
- Key commercial benefits and risks of incorporating predictive biomarkers into oncology drug development.
Highlights of this title:
- It is hoped that the increased adoption of biomarker use in oncology will enable early proof-of-concept studies for novel therapeutic targets; accelerate the adoption of population-enrichment strategies for clinical trial recruitment; and increase the use of biomarker endpoints as surrogates for clinical benefit in oncology clinical trials.
- Advances in imaging analysis technology have shed new light on cancer progression by enabling the precise measurement of small changes in structure and function over time. Image-based biomarkers have been singled out by the FDA as promising tools for every stage of drug development, from preclinical research to the approval process.
- While targeting specific genotypes in clinical trials increases the opportunity to demonstrate clinical benefit, developers are concerned about how an increasingly fragmented cancer market may limit a drugs commercial potential. There is already skepticism among physicians about how readily Pharma will adopt a more personalized approach.
Reasons to order your copy:
- Understand how tumor biomarkers will impact on oncology drug development as the paradigm to targeted treatment evolves.
- Assess opportunities and risks for novel oncology biomarker development and commercialization.
- Drive drug development strategies that incorporate prognostic or predictive biomarkers.
Customers who bought this item also bought
Companion Biomarkers in Drug Development
Biomarkers - Technologies, Markets and Companies
Advances in Biomarkers
Biomarkers 2008
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
What Is the Future Role of Predictive Safety Biomarkers in Drug Development?
Biomarkers: The Future of Next-Generation Drug R&D
Enabling Oncology Diagnostics: Predictive Biomarkers Based on Genes, Proteins, and Pathways
Novel Strategies in Oncology Clinical Trials: The Use of Biological and Imaging Biomarkers
Biomarkers - Advanced Technologies and Global Market (2009-2014)
Cancer, CNS & Cardiovascular Biomarkers: Players, Products and Prospects
Cancer Biomarkers: Players, Products and Prospects (Volume I)
|
|
|
|
